Advertisement

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Deborah Collyar: What's In It for Patients?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




Oct
29
Today In Oncology
How Medicare Advantage and Traditional Medicare Influence Palliative and Hospice Care Implementation
Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage SCLC
TALENT Neoadjuvant T-DXd in HER2-Low Early Breast Cancer
Adding a Chatbot to Cancer Predisposition Visits Improves Risk Knowledge in AYAs
Substudy Validates Perioperative Approach of Systemic Therapy With Radical Prostatectomy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo